QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NASDAQ:SGHT

Sight Sciences (SGHT) Stock Price, News & Analysis

$5.34
+0.16 (+3.09%)
(As of 11:48 AM ET)
Today's Range
$5.14
$5.47
50-Day Range
$4.02
$5.89
52-Week Range
$1.04
$11.20
Volume
34,036 shs
Average Volume
221,423 shs
Market Capitalization
$264.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.60

Sight Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
13.9% Downside
$4.60 Price Target
Short Interest
Bearish
6.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Sight Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$151,250 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.04) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.51 out of 5 stars

Medical Sector

912th out of 939 stocks

Surgical & Medical Instruments Industry

98th out of 98 stocks

SGHT stock logo

About Sight Sciences Stock (NASDAQ:SGHT)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

SGHT Stock Price History

SGHT Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
SGHT Apr 2024 5.000 call
Q4 2023 Sight Sciences Inc Earnings Call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Sight Sciences: Q4 Earnings Insights
Sight Sciences's Earnings: A Preview
Sight Sciences (SGHT) to Expand in Europe With New Launch
See More Headlines
Receive SGHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:SGHT
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.60
High Stock Price Target
$5.50
Low Stock Price Target
$4.00
Potential Upside/Downside
-11.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-55,550,000.00
Pretax Margin
-68.39%

Debt

Sales & Book Value

Annual Sales
$81.06 million
Book Value
$2.47 per share

Miscellaneous

Free Float
36,124,000
Market Cap
$256.67 million
Optionable
Optionable
Beta
2.76
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Paul Badawi (Age 49)
    Co-Founder, President, CEO & Director
    Comp: $920.3k
  • Dr. David Badawi M.D. (Age 54)
    Founder, CTO & Director
  • Mr. Sam Boong Park (Age 63)
    Chief Operating Officer
    Comp: $531.78k
  • Ms. Alison Perry Bauerlein (Age 43)
    CFO & Treasurer
  • Mr. Jeremy B. Hayden (Age 54)
    Chief Legal Officer
  • Mr. Steve R. Tamayo Jr.
    VP and Chief Ethics & Compliance Officer
  • Dr. Reay H. Brown
    Chief Medical Officer
  • Tom Huang
    Head of Corporate Strategy & Development
  • Mr. Matthew W. Link (Age 49)
    Chief Commercial Officer
  • Mr. Stephen B. Thau J.D.
    Secretary

SGHT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sight Sciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sight Sciences in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SGHT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGHT, but not buy additional shares or sell existing shares.
View SGHT analyst ratings
or view top-rated stocks.

What is Sight Sciences' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price objectives for Sight Sciences' stock. Their SGHT share price targets range from $4.00 to $5.50. On average, they expect the company's stock price to reach $4.60 in the next twelve months. This suggests that the stock has a possible downside of 13.9%.
View analysts price targets for SGHT
or view top-rated stocks among Wall Street analysts.

How have SGHT shares performed in 2024?

Sight Sciences' stock was trading at $5.16 at the beginning of the year. Since then, SGHT shares have increased by 3.5% and is now trading at $5.34.
View the best growth stocks for 2024 here
.

When is Sight Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our SGHT earnings forecast
.

How were Sight Sciences' earnings last quarter?

Sight Sciences, Inc. (NASDAQ:SGHT) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13. The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative net margin of 68.53% and a negative trailing twelve-month return on equity of 41.94%. During the same period last year, the business earned ($0.35) earnings per share.

What guidance has Sight Sciences issued on next quarter's earnings?

Sight Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.0 million-$85.0 million, compared to the consensus revenue estimate of $82.4 million.

When did Sight Sciences IPO?

Sight Sciences (SGHT) raised $150 million in an IPO on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share.

Who are Sight Sciences' major shareholders?

Sight Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UBS Group AG (5.94%), Jackson Square Partners LLC (3.34%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Northern Trust Corp (0.41%) and Charles Schwab Investment Management Inc. (0.40%). Insiders that own company stock include D1 Capital Partners LP, David Badawi, Jeremy B Hayden, Jesse Selnick, Paul Badawi, Sam Boong Park and Staffan Encrantz.
View institutional ownership trends
.

How do I buy shares of Sight Sciences?

Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGHT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners